Bio Green Med Solution (BGMS) Cost of Revenue (2010 - 2026)

Bio Green Med Solution (BGMS) posted quarterly Cost of Revenue of $635000.0 for Q1 2026, up 16.51% quarter-over-quarter from $545000.0 in Q4 2025.

Analysis

Bio Green Med Solution (BGMS) Cost of Revenue (2010 - 2026) Analysis & Trends

Bio Green Med Solution (BGMS) has reported Cost of Revenue for 5 consecutive years, with $635000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Cost of Revenue changed N/A year-over-year to $635000.0; the TTM figure through Mar 2026 stood at $1.4 million (changed N/A YoY), while the FY2025 annual figure was $609000.0, changed N/A from the prior year.
Cost of Revenue climbed to $635000.0 in Q1 2026 per BGMS's latest filing, from $545000.0 in the prior quarter.
Across five years, Cost of Revenue topped out at $635000.0 in Q1 2026 and bottomed at $64000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	141.56 Bn	133.71 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	87.63 Bn	79.64 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.65 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	60.24 Bn	55.10 Bn	52.00 Mn	93.00 Mn
5	Revolution Medicines	44.13 Bn	44.13 Bn	-	-
6	BeOne Medicines	40.46 Bn	35.36 Bn	1.53 Bn	174.53 Mn
7	Alnylam Pharmaceuticals	35.86 Bn	32.56 Bn	992.69 Mn	298.26 Mn
8	Royalty Pharma	28.00 Bn	27.16 Bn	-	-
9	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	67.21 Mn
10	Bio Green Med Solution	4.68 Mn	886,595.10	79,000.00	257,000.00

Historic Data

Download Data